Prescripción off-label de antiasmáticos en Atención Primaria

Alonso, I. Casares; Garcinuño, Alfredo Cano; Quirós, Alfredo Blanco; García, Isabel Pérez

doi:10.4321/s1139-76322015000400005

Cited by 1 publication

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beta-2-agonists should not be used in children with infundibular pulmonary stenosis as beta-blockers may be prescribed to prevent hypoxic spells in these children while awaiting surgery 40. While over 50% of children in hospitals are administered ‘unlicensed’ or ‘off-label’ medicines,41 42 a Spanish study reported that 16% of antiasthmatics dispensed by community pharmacies for use by children were ‘off-label’ and that the seasonal variations suggested that these were prescribed to treat respiratory infections in young children rather than asthma 43. We do not have information about off-label use in our study but the indications and age limits for prescribing off-label antiasthmatics are likely to differ between countries.…”

Section: Discussionmentioning

confidence: 95%

Antiasthmatic prescriptions in children with and without congenital anomalies: a population-based study

Divin,

Given,

Tan

et al. 2023

BMJ Open

View full text Add to dashboard Cite

ObjectivesTo explore the risk of being prescribed/dispensed medications for respiratory symptoms and breathing difficulties in children with and without congenital anomalies.DesignA EUROlinkCAT population-based data linkage cohort study. Data on children with and without congenital anomalies were linked to prescription databases to identify children who did/did not receive antiasthmatic prescriptions. Data were analysed by age, European region, class of antiasthmatic, anomaly, sex, gestational age and birth cohort.SettingChildren born 2000–2014 in six regions within five European countries.Participants60 662 children with congenital anomalies and 1 722 912 reference children up to age 10 years.Primary outcome measureRelative risks (RR) of >1 antiasthmatic prescription in a year, identified using Anatomical Therapeutic Chemical classification codes beginning with R03.ResultsThere were significant differences in the prescribing of antiasthmatics in the six regions. Children with congenital anomalies had a significantly higher risk of being prescribed antiasthmatics (RR 1.41, 95% CI 1.35 to 1.48) compared with reference children. The increased risk was consistent across all regions and all age groups. Children with congenital anomalies were more likely to be prescribed beta-2 agonists (RR 1.71, 95% CI 1.60 to 1.83) and inhaled corticosteroids (RR 1.74, 95% CI 1.61 to 1.87). Children with oesophageal atresia, genetic syndromes and chromosomal anomalies had over twice the risk of being prescribed antiasthmatics compared with reference children. Children with congenital anomalies born <32 weeks gestational age were over twice as likely to be prescribed antiasthmatics than those born at term (RR 2.20, 95% CI 2.10 to 2.30).ConclusionThis study documents the additional burden of respiratory symptoms and breathing difficulties for children with congenital anomalies, particularly those born preterm, compared with children without congenital anomalies in the first 10 years of life. These findings are beneficial to clinicians and healthcare providers as they identify children with greater morbidity associated with respiratory symptoms, as indicated by antiasthmatic prescriptions.

show abstract

Section: Discussionmentioning

confidence: 95%